WuXi Apptec Resumes Operations at Wuhan Site
The facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.
WuXi AppTec announced on March 10, 2020 that it has resumed operations at its Wuhan, China, site in agreement with local regulations and global novel coronavirus (COVID-19) health and safety guidelines.
According to a company press release, the facility, which handles discovery chemistry services, will accelerate its operations over the next few weeks while taking precautions to guarantee the health and safety of its employees across every site.
“We are working with our employees and suppliers to reach steady state operations at our Wuhan site as soon as possible,” said Steve Yang, executive vice-president and chief business officer of WuXi AppTec, in a company press release. “We value our customers’ contributions to the healthcare field and put them first by providing timely and world-class quality service and continue to do the right thing for patients-a goal that WuXi AppTec has pursued since its founding.”
Source: WuXi AppTec
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
